drugset / Trial / NCT01430091

A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet

NCT01430091

Phase 1 Completed 18 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelTreatment

Summary

This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.

Timeline

Start
2011-09
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prasugrel Small molecule 5 mg Oral

Indications